Olapag
Generic Name
Olaparib
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olapag 25 mg tablet | ৳ 500.00 | ৳ 5,000.00 |
Description
Overview of the medicine
Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated for various types of cancer, particularly those with BRCA gene mutations. It works by blocking enzymes involved in DNA repair, leading to cancer cell death.
Uses & Indications
Dosage
Adults
Recommended dose is typically 300 mg (as two 150 mg tablets) taken orally twice daily, with or without food. The 25 mg tablet may be used for dose titration or specific protocols.
Elderly
No specific dose adjustment required based on age alone. Monitor for adverse reactions.
Renal_impairment
For moderate renal impairment (CrCl 31-50 mL/min), reduce dose to 200 mg twice daily. For severe renal impairment (CrCl < 30 mL/min), use with caution; no specific recommendations available, refer to specialist.
How to Take
Administer orally, with or without food. Swallow tablets whole; do not chew, crush, or split. Take doses approximately 12 hours apart.
Mechanism of Action
Olaparib selectively inhibits PARP-1, PARP-2, and PARP-3 enzymes, which are involved in DNA repair. By inhibiting PARP, Olaparib prevents single-strand break repair, leading to an accumulation of DNA damage and ultimately cell death in cancer cells, especially those with homologous recombination deficiency (e.g., BRCA mutations).
Pharmacokinetics
Onset
Not specified in terms of clinical onset; pharmacological effect begins with PARP inhibition.
Excretion
Mainly via feces (44%) and urine (42%), primarily as metabolites.
Half life
Approximately 15-17 hours.
Absorption
Rapidly absorbed; peak plasma concentrations reached within 1.5 hours.
Metabolism
Primarily metabolized by CYP3A4/5, with minor contributions from other CYP enzymes.
Side Effects
Contraindications
- Known hypersensitivity to Olaparib or any component of the formulation
- Breast-feeding during treatment and for 1 month after the last dose
Drug Interactions
Strong CYP3A inducers (e.g., rifampicin, phenytoin)
Concomitant use decreases olaparib exposure; avoid concomitant use.
Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin)
Concomitant use increases olaparib exposure; avoid or reduce olaparib dose.
Storage
Store at room temperature (20°C to 25°C). Excursions permitted to 15°C to 30°C. Protect from moisture.
Overdose
No specific antidote for Olaparib overdose. In case of an overdose, symptomatic and supportive measures should be initiated. Contact a poison control center for current management recommendations.
Pregnancy & Lactation
Olaparib can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Do not breast-feed during treatment and for 1 month after the last dose.
Side Effects
Contraindications
- Known hypersensitivity to Olaparib or any component of the formulation
- Breast-feeding during treatment and for 1 month after the last dose
Drug Interactions
Strong CYP3A inducers (e.g., rifampicin, phenytoin)
Concomitant use decreases olaparib exposure; avoid concomitant use.
Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin)
Concomitant use increases olaparib exposure; avoid or reduce olaparib dose.
Storage
Store at room temperature (20°C to 25°C). Excursions permitted to 15°C to 30°C. Protect from moisture.
Overdose
No specific antidote for Olaparib overdose. In case of an overdose, symptomatic and supportive measures should be initiated. Contact a poison control center for current management recommendations.
Pregnancy & Lactation
Olaparib can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. Do not breast-feed during treatment and for 1 month after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented
Clinical Trials
Olaparib has been extensively studied in several pivotal clinical trials (e.g., SOLO-1, SOLO-2, PAOLA-1, OLYMPIAD, PROfound) demonstrating efficacy in BRCA-mutated and HRR-deficient cancers.
Lab Monitoring
- Complete blood count (CBC) with differential, monitored weekly for the first month, then monthly for the next 11 months, and periodically thereafter.
- Renal function tests (creatinine, BUN)
- Liver function tests (ALT, AST, bilirubin)
Doctor Notes
- Confirm BRCA or HRR gene mutation status before initiating treatment.
- Monitor complete blood counts weekly for the first month, then monthly.
- Educate patients on symptoms of MDS/AML and pneumonitis.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not change your dose or stop taking Olaparib without talking to your doctor.
- Inform your doctor about all medicines, vitamins, and herbal supplements you are taking.
Missed Dose Advice
If a dose is missed, do not take an extra dose to make up for the missed dose. Take the next dose at its scheduled time. Do not take two doses at the same time.
Driving Precautions
Olaparib may cause fatigue, dizziness, or weakness. Patients should be cautioned about driving or operating machinery if they experience these symptoms.
Lifestyle Advice
- Maintain good hydration.
- Report any unusual bleeding or bruising, fever, shortness of breath, or new skin rash to your doctor immediately.
- Avoid strenuous activities if you experience severe fatigue or anemia.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olapag Brand
Other medicines available under the same brand name
